Kihira K et al. |
Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930904
|
Kamada T et al. |
Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of helicobacter pylori in smokers. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930905
|
Savarino V et al. |
OAM for cure of Helicobacter pylori infection. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10930908
|
Perri F et al. |
Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421877
|
Perri F et al. |
Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421878
|
Pilotto A et al. |
Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11421879
|
Fischbach L and Evans EL |
Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17635369
|
Gisbert JP et al. |
7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15882246
|
Nista EC et al. |
Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15882245
|
Boixeda D et al. |
Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12182745
|
Sierra F et al. |
Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. |
2013 |
Aliment. Pharmacol. Ther. |
pmid:23656465
|
Madisch A et al. |
Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16441467
|
Borody TJ et al. |
Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16441468
|
Veldhuyzen Van Zanten S et al. |
One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12786632
|
Laine L |
Review article: esomeprazole in the treatment of Helicobacter pylori. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12047270
|
Fakheri H et al. |
Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11207517
|
Nagahara A et al. |
Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11207518
|
Bardhan KD et al. |
Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632646
|
Cammarota G et al. |
Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632648
|
Gasbarrini A et al. |
Efficacy of a multistep strategy for Helicobacter pylori eradication. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632649
|
Chan FK et al. |
Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10632651
|
Pipkin GA et al. |
Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9768524
|
Vakil N et al. |
Duplicate breath testing to confirm eradication of Helicobacter pylori: incremental benefit and cost in 419 patients. |
2008 |
Aliment. Pharmacol. Ther. |
pmid:18774949
|
Shokri-Shirvani J et al. |
Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. |
2016 |
Aliment. Pharmacol. Ther. |
pmid:27137738
|
Axon AT et al. |
Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9042977
|
Labenz J et al. |
One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9042978
|
Labenz J et al. |
Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9042979
|
Calvet X et al. |
One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12144575
|
Di Caro S et al. |
Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11876707
|
Savarino V et al. |
Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:9892878
|
Spinzi GC et al. |
Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9663722
|
Bazzoli F et al. |
Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9663723
|
Pozzato P et al. |
Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9663724
|
Goh KL et al. |
Comparison of two 1-week low-dose omeprazole triple therapies--optimal treatment for Helicobacter pylori infection? |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9663838
|
Wong BC et al. |
Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11736727
|
Kolkman JJ et al. |
Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9663840
|
O'Connor HJ et al. |
Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9570262
|
Scott BB |
Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9570263
|
Goodgame RW et al. |
Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11736715
|
Sheu BS et al. |
The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12755841
|
Gudjonsson H et al. |
High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9845401
|
Tam YH et al. |
Seven-day is more effective than 4-day ranitidine bismuth citrate-based triple therapy in eradication of Helicobacter pylori in children: a prospective randomized study. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16803605
|
Sengupta S et al. |
Effect of oral clarithromycin on gall-bladder motility in normal subjects and those with gall-stones. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16803607
|
Perri F et al. |
Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14535875
|
Jung YS et al. |
Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28497487
|
Klok RM et al. |
Continued utilization and costs of proton pump inhibitors after Helicobacter pylori eradication in chronic users of gastrointestinal drugs. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11966514
|
Tsuzuki T et al. |
Clarithromycin increases the release of heat shock protein B from Helicobacter pylori. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11966545
|
Ellenrieder V et al. |
Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9701524
|
Lim AG et al. |
Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9218079
|
McNulty CA et al. |
Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? |
2012 |
Aliment. Pharmacol. Ther. |
pmid:22469191
|